AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 91 min read$NBIX

Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026

Neurocrine Biosciences (NBIX) officer Eric Benevich plans to sell 2,154 shares via stock options on or around September 9, 2026, according to a Rule 144 notice. The sale will be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

Original reporting
stocktitan.net
Published Sep 9, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NBIX
Neutral
low confidence
Mentioned
$NBIX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to materially affect NBIX price, but it provides transparency on insider activity.

02

Market read

Primary insider sale filing with limited market impact.

03

What to watch

Potential cumulative effect if multiple insiders sell around the same time.

Relevance 4/10Novelty 4/10Timing: sale scheduled for Sep 9, 2026

Background

Rule 144 filings disclose planned sales of restricted shares by insiders, informing investors of upcoming supply.

Company-level read

Ticker impact

$NBIXNeutralLow confidence
Context

Rule 144 filing shows officer Eric Benevich will sell 2,154 NBIX shares on Sep 9, 2026.

Expected impact

negligible to slight downward pressure on NBIX near the sale date

Evidence & confidence

Only 2,154 shares (~$X million) are being sold; such a modest amount is unlikely to move the market.

Market effects

Sector

Minimal effect on biotech sector; insider sales are routine.

Regional

No regional impact.

Global

None

Counterpoint

What could challenge this read

If the insider is cashing out due to negative outlook, the sale could foreshadow a short-term dip.

Key entities

  • Officer
    Eric Benevich

    NBIX officer planning the share sale.

  • Broker
    Morgan Stanley Smith Barney LLC

    Designated broker for the Rule 144 transaction.

Read at source← All news

Related articles

SEP 18
$NBIXMedAI 8/10

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

Neurocrine Biosciences (NBIX) reported positive Phase 4 study results for INGREZZA, showing significant patient improvement in tardive dyskinesia. The company also reported Q2 revenue growth of 39% to $959M, with INGREZZA sales up 15%. Neurocrine acquired Soleno Therapeutics, reducing cash reserves but expanding its drug portfolio. The stock trades at a forward P/E of 14.88.

insidermonkey.com2 min
AUG 12
$NBIXMed

Why is Neurocrine Biosciences stock sliding today?

Neurocrine Biosciences (NBIX) shares fell about 3.1% to $156.94 after three Prader-Willi patient groups issued a joint statement citing post-marketing safety data for Neurocrine’s Vykat XR, including seven patient deaths and 100+ serious adverse events reported to the FDA. The groups did not claim causality. CEO Kyle Gano disputed a link. Investors also weighed INGREZZA drug-pricing concerns; Q2 2026 revenue was reported above $950M.

investing.com6 min